Framycetin sulfate
(Synonyms: 新霉素B硫酸盐,Neomycin B sulfate; Fradiomycin B sulfate) 目录号 : GC64757
Framycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM, and competes for specific divalent metal ion binding sites in RNase P RNA, also inhibits hammerhead ribozyme with a Ki of 13.5 μM.
Cas No.:4146-30-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Framycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM, and competes for specific divalent metal ion binding sites in RNase P RNA, also inhibits hammerhead ribozyme with a Ki of 13.5 μM.
[1] Mikkelsen NE, et al. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6155-60.
| Cas No. | 4146-30-9 | SDF | Download SDF |
| 别名 | 新霉素B硫酸盐,Neomycin B sulfate; Fradiomycin B sulfate | ||
| 分子式 | C23H52N6O25S3 | 分子量 | 908.88 |
| 溶解度 | Water : 250 mg/mL (275.06 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1003 mL | 5.5013 mL | 11.0026 mL |
| 5 mM | 0.2201 mL | 1.1003 mL | 2.2005 mL |
| 10 mM | 0.11 mL | 0.5501 mL | 1.1003 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Comparative efficacy of two polyherbal creams with Framycetin sulfate on diabetic wound model in rats
J Ayurveda Integr Med 2016 Apr-Jun;7(2):83-7.PMID:27449205DOI:10.1016/j.jaim.2015.09.004.
Background: Diabetes mellitus is one of the metabolic disorders that impede normal steps of wound healing process. Worldwide, 15% of the 200 million diabetics suffer from diabetic wounds. Diabetic complications, such as foot ulcer, impose major public health burdens worldwide. Objective: The present study was carried out to evaluate comparative efficacy of polyherbal creams with Framycetin sulfate cream on diabetic rats using incision and excision wound models. Materials and methods: Alloxan (120 mg/kg, intraperitoneal) induced diabetic rat models (incision and excision models) were used to evaluate wound healing effect of cream A, B, and Framycetin sulfate. Cream A and B were applied for a period of 10 and 20 days for incision and excision wound models, respectively. Incision wound model was used to assess the effect on breaking strength. Wound contraction and epithelialization period were measured using excision wound model. The data were analyzed by one-way ANOVA followed by Bonferroni post-test. Results: Tensile strength of the animals treated with cream B (941.66 ± 15.36) was found to be significantly greater (P < 0.001) as compared to tensile strength of the animals treated with cream A (825 ± 22.36). Wound treated with cream B was found to heal significantly (P < 0.001) faster (day 17) as compared to wounds treated with Framycetin sulfate (day 21). Conclusions: Cream B was found to be more effective wound healing agent than cream A and Framycetin sulfate cream in treating diabetic wounds.
Analysis of neomycin sulfate and Framycetin sulfate by high-performance liquid chromatography using evaporative light scattering detection
J Chromatogr A 2005 Sep 16;1087(1-2):236-44.PMID:16130719DOI:10.1016/j.chroma.2005.05.054.
A rapid and simple method for the determination of main components and related substances of both neomycin sulfate and Framycetin sulfate by HPLC and evaporative light scattering detection (ELSD) is described. The method was also used to determine the neomycin B and the sample sulfate content. Detection and quantitation of aminoglycoside antibiotics are problematic because of the lack of UV absorbing chromophore. The use of a universal detector avoids the need for sample derivatization or use of specific detector based on pulsed amperometry described to be difficult in routine assays. Separation was performed with a Polaris C18 150 mm x 4.6 mm i.d., 3 microm reversed-phase column with a solution of 170mM trifluoroacetic acid (TFA) mobile phase at a flow rate of 0.2 mL/min. The chromatographic parameters were optimized with the help of experimental design software. Mass spectrometry (MS) was employed to confirm the ELSD profile. The final method was validated using methodology described by the International Conference of Harmonization in the field of Active Pharmaceutical Ingredients. Commercial samples of different sources were analyzed and results were in good agreement with specifications of the European Pharmacopoeia.
Influence of an intramammary infusion at drying-off of combined penethamate hydriodide, benethamine penicillin, and Framycetin sulfate on intramammary infections and somatic cell counts in dairy sheep
J Dairy Sci 2008 Sep;91(9):3459-66.PMID:18765604DOI:10.3168/jds.2007-0842.
The dynamics of intramammary infection (IMI) during the dry period were studied in 435 half-udders of 229 Assaf ewes, belonging to 2 flocks with high and medium IMI prevalences. Ewes were randomly assigned to 2 lots: 1) treated lot (TL) with 223 half-udders (118 ewes), which received complete dry therapy (1 syringe/teat) of an antibiotic combination containing 100 mg of penethamate hydriodide, 280 mg of benethamine penicillin, and 100 mg of Framycetin sulfate, and 2) control lot (CL) with 212 nontreated half-udders (111 ewes). Two samplings per half-udder were carried out on 2 different days in the 5 d preceding drying-off, and 2 other samplings were again carried out in the 5 first d of the postpartum period. The length of the dry period averaged 109.0 d. Cure, persistent infections, reinfection, and new infection rates were 81.7, 12.8, 5.5, and 7.9%, respectively, for TL and 13.3, 70.4, 16.3, and 22.8%, respectively, for the CL. The prevalence of IMI decreased significantly from 48.9% at drying-off to 13.0% at lambing for the TL, but it did not vary for the CL (46.2 and 52.4%, respectively). Within the TL, IMI prevalence significantly diminished for Staphylococcus (41.3 to 9.9%) and Streptococcus (5.8 to 1.8%) genera, and more specifically this decrease was most evident for Staphylococcus epidermidis and Streptococcus agalactiae species. Log somatic cell count (SCC) diminished significantly between drying-off (5.68) and lambing (5.33) in the TL, whereas log SCC did not vary in the CL (5.61 vs. 5.66). This SCC reduction was very significant in the flock with the greater IMI prevalence. As a conclusion, the antibiotic formulation used as dry therapy drastically diminished IMI prevalence and SCC during the dry period in dairy ewes as a result of greater IMI cure rates and lower reinfection and new infection rates in the TL compared with the CL.
Contact allergy to neomycin sulfate: results of a multifactorial analysis
Pharmacoepidemiol Drug Saf 2005 Oct;14(10):725-33.PMID:15880442DOI:10.1002/pds.1117.
Purpose: To perform a comprehensive, multifactorial analysis of potential risk factors (demographic and clinical) for contact allergy to neomycin sulfate, a common adverse reaction resulting from the topical use of this drug; especially in some subgroups of the population. Methods: Retrospective analysis of allergy test data of the Information Network of Departments of Dermatology (IVDK, www.ivdk.org) between 1998 and 2003, including all patients patch tested with a standard screening series because of suspected allergic contact dermatitis (ACD). As one outcome, a positive (allergic) test reaction to neomycin sulfate was considered. An alternative outcome included only those patients with a positive test to neomycin sulfate and a final diagnosis of ACD. The association between outcome and potential risk factors was analyzed with Poisson regression analysis, deriving prevalence ratios (PR) as risk estimates. Results: Of the 47,559 patients tested, 2.5% had positive reactions to neomycin sulfate, while in 1.1% ACD was additionally diagnosed. The results of the multifactorial analysis indicated that the risk of both outcomes decreased slightly during the period covered; was higher among patients with leg dermatitis; varied significantly with age and increased progressively with the number of additional positive reactions to other standard series allergens. Cross-reactivity to other, selectively tested, aminoglycoside antibiotics was substantial (kappa = 0.67; 95%CI: 0.63-0.71) for Framycetin sulfate, to low (kappa = 0.33; 95%CI: 0.27-0.37) for gentamicin sulfate. Conclusions: The prevalence of contact sensitization to neomycin sulfate was noteworthy among patients patch tested in the IVDK centers. Supplementing clinical epidemiology, neomycin contact allergy has been estimated to be relatively common even on the level of the unselected population (prevalence approx. 1%). Hence, the topical use of neomycin sulfate by patients should be carefully monitored, considering its potential to induce ACD, with emphasis on subgroups at risk.